A phase II, prospective, randomized, open-label study to evaluate the immune responses of FluMist compared with trivalent inactivated vaccine (TIV) in children 12 to less than 36 months of age

Trial Profile

A phase II, prospective, randomized, open-label study to evaluate the immune responses of FluMist compared with trivalent inactivated vaccine (TIV) in children 12 to less than 36 months of age

Completed
Phase of Trial: Phase II

Latest Information Update: 04 May 2010

At a glance

  • Drugs Influenza virus vaccine; Influenza virus vaccine live
  • Indications Influenza A virus H1N1 subtype; Influenza B virus infections; Influenza virus infections
  • Focus Pharmacodynamics; Pharmacogenomic
  • Sponsors MedImmune
  • Most Recent Events

    • 04 May 2010 Results of transcriptional analysis were presented at the Annual Meeting of the Pediatric Academic Societies 2010.
    • 09 Feb 2010 Actual number of patients (101) added as reported by ClinicalTrials.gov record
    • 01 Nov 2009 Results reported at 47th Annual IDSA meeting, according to MedImmune media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top